Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy

Medical Decision Making

Volumn 37, Issue 7, 2017, Pages 770-778

  Van Klaveren, David ^a,b   Wong, John B ^b   Kent, David M ^b   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

formulary decision making; outcomes research; translating research into practice

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE;

AGE DISTRIBUTION; AGED; COST BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; LIFE TABLE; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SEVERITY OF ILLNESS INDEX; SEX RATIO; STATISTICAL BIAS; STATISTICAL MODEL; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIAS; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIFE EXPECTANCY; LIFE TABLES; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 85028663946     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17696994     Document Type: Article

References (27)

1. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003; 6: 9-17.
2. Stevens W, Normand C., Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. Soc Sci Med. 2004; 58: 315-20.
3. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16: 231-50.
4. Basu A, Meltzer D., Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007; 27: 112-27.
5. Sculpher M., Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008; 26: 799-806.
6. Sculpher M., Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. Value Health. 2010; 13 Suppl 1: S18-21.
7. Ioannidis JPA, Garber AM., Individualized Cost-Effectiveness Analysis. PLoS Med. 2011; 8: e1001058.
8. Vickers AJ, Kent DM., The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk. Ann Intern Med. 2015; 162: 866-7.
9. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP., Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol. 2004; 57: 843-52.
10. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995; 91: 1659-68.
11. Parakh K, Thombs BD, Bhat U, Fauerbach JA, Bush DE, Ziegelstein RC., Long-term Significance of Killip Class and Left Ventricular Systolic Dysfunction. Am J Med. 2008; 121: 1015-8.
12. de Carvalho LP, Gao F, Chen Q, et al. Long-Term Prognosis and Risk Heterogeneity of Heart Failure Complicating Acute Myocardial Infarction. Am J Cardiol. 2015; 115: 872-8.
13. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995; 332: 1418-24.
14. Califf RM, Woodlief LH, Harrell FE Jr., et al. Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Am Heart J. 1997; 133: 630-9.
15. Arias E., United States Life Tables, 2009. National Vital Statistics Reports 2014; 62.
16. Killip T 3rd, Kimball JT., Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967; 20: 457-64.
17. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.3-900051-07-0ed2013.
18. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014; 371: 1793-802.
19. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med. 2012; 157: 242-50.
20. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013; 368: 728-36.
21. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013; 369: 245-54.
22. Rosenberg MA, Feuer EJ, Yu B, et al. Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal. 2012; 32 Suppl 1: S25-38.
23. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005; 8: 521-33.
24. Steyerberg EW., Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York: Springer; 2009.
25. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS., Screening for prostate cancer. A decision analytic view. JAMA. 1994; 272: 773-80.
26. Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW., The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making. 1998; 18: 376-80.
27. Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail. 2014; 2: 159-65.